Novartis gains FDA approval for Gilenya drug

 FRANKFURT (MarketWatch) -- Swiss pharmaceutical giant Novartis AG /quotes/comstock/13*!nvs/quotes/nls/nvs (NVS 56.38, +0.21, +0.38%) /quotes/comstock/06p!novn (CH:NOVN 55.45, -1.00, -1.77%) said Wednesday that the Food and Drug Administration approved its multiple-sclerosis drug Gilenya, making it the first oral treatment indicated for relapsing forms of the disease available in the U.S. Gilenya reduces the frequency of MS relapses, or flare-ups, and helps slow the build-up of some of the physical problems caused by the disease, Novartis said. "A new treatment option that offers significant efficacy in the convenience of a capsule is a welcome alternative to frequent injections for individuals living with this chronic disease," said Nicholas LaRocca from the National Multiple Sclerosis Society in a

 FRANKFURT (MarketWatch) -- Swiss pharmaceutical giant Novartis AG /quotes/comstock/13*!nvs/quotes/nls/nvs (NVS 56.38, +0.21, +0.38%) /quotes/comstock/06p!novn (CH:NOVN 55.45, -1.00, -1.77%) said Wednesday that the Food and Drug Administration approved its multiple-sclerosis drug Gilenya, making it the first oral treatment indicated for relapsing forms of the disease available in the U.S. Gilenya reduces the frequency of MS relapses, or flare-ups, and helps slow the build-up of some of the physical problems caused by the disease, Novartis said. "A new treatment option that offers significant efficacy in the convenience of a capsule is a welcome alternative to frequent injections for individuals living with this chronic disease," said Nicholas LaRocca from the National Multiple Sclerosis Society in a

Read more >>